Dermatitis Drugs Market is Expected to Reach $7.1Bn by 2023

The global dermatitis drugs market is expected to decline from $5.4 billion in 2019 to $4.7 billion in 2020 at a compound annual growth rate (CAGR) of -13.9%. The decline is mainly because of drop in sales due to the lockdown measures to contain COVID-19 spread. Apart from restricting non-emergency medical services, new rules of the governments across the globe has forced many companies in the dermatology drug market to halt their business operations which has impacted the market growth. The market is then expected to recover and grow at a CAGR of 5.7% from 2021 and reach $7.1 billion in 2023.

The dermatitis drugs market consists of sales of dermatitis drugs such as corticosteroids, calcineurin inhibitors, PDE4 inhibitors which are used to cure inflammation of the outer layer of the body, characterized by itchy rashes on swollen and reddened skin.

The Dermatitis market has witnessed a trend of increasing Mergers and Acquisitions (M&As), done with the purpose of business expansion and increasing visibility. M&As are playing a significant role in today`s world and are assumed to expand this market in the years to come. The vendors in this industry are focusing on collaboration and partnerships to expand their portfolio and improve market presence. Companies are also strategically making M&As with a view to reduce competition and increase the scalability of their business.

Dermatitis Drugs Market Segmentation:

  • By Drug Class
    • Corticosteroids
    • Emollients/Moisturizers
    • Antihistamines
    • Calcineurin Inhibitors
    • Antibiotics
    • Immunomodulators
    • Interleukin Inhibitors
  • By Distribution Channel
    • Hospital
    • Retail Pharmacies
    • Drug Stores
    • Online Or Mail Pharmacies
  • By Route Of Application
    • Topical
    • Oral
    • Injectable
  • By Application
    • Cancer
    • Blood Disorders
    • Chronic Diseases
    • Infectious Diseases


Some of the key players involved in the dermatitis drugs market are LEO Pharma A/S, Novartis AG, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi S.A.

About US:
The Business Research Company has published over 1000 industry reports, covering over 2500 market segments and 60 geographies. The reports draw on 150,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. The reports are updated with a detailed analysis of the impact of COVID-19 on various markets after WHO declared COVID-19 as a pandemic.

Contact Information:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293

Related Posts

Subscribe Our Newsletter